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Metadoxine is composed of pyroglutamic acid and vitamin B6. Administrations of metadoxine are indicated in cases of 
acute alcohol intoxication or in chronic alcoholism. 
Objectives 
To reference all available clinical trials investigating the effects of metadoxine on humans. A focus was put on alcohol 
intoxication and chronic alcoholism, alcohol abstinence and survival rates. Adverse events were also taken into 
consideration. Finally, potential roles of metadoxine in treating disorders of the central nervous system will be assessed. 
Methods 
PRISMA guidelines were followed. Computerised literature searches were performed in July 2017 to retrieve all clinical 
trials investigating metadoxine from the MEDLINE®, the European Union Clinical Trials Register and the 
ClinicalTrials.gov databases, using the following equation: “metadoxine”. Inclusion criteria were all published clinical 
trials investigating metadoxine in humans, regardless of outcome measures. Exclusion criteria were articles not 
abstracted, in vitro studies, studies in rodents, retrospective studies and reviews. 
Results 
Sixteen studies were included. Evidence suggests that metadoxine appears safe to use, as it rarely induced adverse events 
(reported in 7 out of the 7 studies measuring safety/tolerability). Moreover, metadoxine seems efficient in treating acute 
alcohol intoxication (2/2 studies) as well as improving liver functions following chronic alcoholism (4/5 studies). 
Finally, currently on-going clinical trials will reveal if metadoxine could be indicated in attention deficit and 
hyperactivity disorders as well as fragile X syndrome. 
Conclusion 
Metadoxine appears safe to use and seems efficient to improve liver functions following alcohol-related diseases. 
Further clinical trials will be necessary to determine if metadoxine can be promising for treating brain disorders. 
PROSPERO registration number: CRD42017072964. 







  Metadoxine is synthesised in vitro by salification (crystallisation) of two molecules. As 
shown in Figure 1, the chemical formula is composed of an ion pairing between L-2-pyrrolidone-
5-carboxylate (pyroglutamic acid) and pyridoxine (a form of vitamin B6) [1,2]. In metadoxine, 
pyroglutamic acid and vitamin B6 (1:1 ratio) have been shown to act synergically [1]. Although not 
physically bound, both vitamin B6 and pyroglutamic acid are electrically linked via an ion-pair salt 
to form metadoxine (Figure 1). Here, “salt” refers to the chemical interaction between an anion and 
a cation, respectively formed by pyroglutamic acid (acid, negatively charged) and vitamin B6 (base, 
positively charged). 
 
  Vitamin B6 is found in many food items such as cereals, fish, starchy vegetables, non-citrus 
fruits, egg yolks and pork [3–5]. As a co-enzyme, vitamin B6 can perform decarboxylation, 
transamination, deamination, racemization and desulfhydration reactions [6]. Furthermore, vitamin 
B6-dependent pathways include glycogenolysis, the synthesis of several neurotransmitters 
(dopamine, epinephrine, norepinephrine, gamma aminobutyric acid and serotonin) as well as several 
endogenous compounds such as taurine, histamine, ceramide and haemoglobin [7–10]. Figure 2 
summarises non-exhaustively the metabolic pathways involving vitamin B6 (as pyridoxal 5’-
phosphate, its active form).  
 
  Pyroglutamic acid was discovered in 1882 by Haitinger as being the result of heating 
glutamate to 180oC. It is found at the centre of both glutamate and glutamine metabolisms [11], as 
seen in Figure 3. Moreover, pyroglutamic acid is a naturally-occurring amino acid found in a few 
food items such as parmesan [12] and yoghurt [13]. Under artificial conditions (acidic, alkaline or 
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temperatures above 78oC), glutamate and glutamine can spontaneously transform into pyroglutamic 
acid [14–16]. Such results could explain the presence of pyroglutamic acid in some diets as a result 
of heating glutamate/glutamine-rich food [17]. Pyroglutamic acid can be dosed in aqueous 
compartments such as the cerebrospinal fluid and urine, with respective levels of 0.06 and 0.19 
µmoles/ml [18]. Interestingly, in human serum, spontaneous cyclisation of glutamine can lead to 
the formation of pyroglutamic acid [15]. Finally, pyroglutamic acid is also found at concentrations 
below 10 µM  in human serum [15,19] and several other organs in the rat, guinea pig and rabbit, 
such as the lungs, the heart, the liver, the spleen and the brain [18]. 
 
  In humans, metadoxine has a short half-life, ranging between 40 to 60 minutes when given 
orally or intravenously [1,20]. Bioavailability is considered high, as pharmacokinetic studies have 
demonstrated a range of 60-80%, with wide tissue distribution [1]. Excretion is performed equally 
through urine and faeces [1]. Dosing regimens can vary largely. Indeed, doses of metadoxine 
administered to patients depend entirely upon the physiopathology they are intended for, and will 
thus be discussed later. Side effects following metadoxine treatments remain rare.  
 
  Alcohol is a widely used psychoactive drug, mostly in western countries [21,22]. The 
psychoactive effects of alcohol are attributed to the concentration of ethanol in alcoholic beverages 
[23]. Ethanol metabolism is more efficient in the liver than in the stomach, due to greater levels of 
alcohol metabolising enzymes in the liver [24,25]. Moreover, gastric first-pass metabolism accounts 
for 10% of total alcohol metabolism, while the remaining 90% occurs in the liver [22]. Ethanol 
consumption leads to enhanced hepatic levels of cytochrome P-450 [26–29]. Ethanol can be 
degraded by two different pathways. On the one hand, the cytochrome P-450 CYP2E1 converts 
ethanol into acetaldehyde in the endoplasmic reticulum [25], leading to the formation of reactive 
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oxygen species. On the other hand, ethanol can be degraded into acetaldehyde by the alcohol 
dehydrogenase route in the liver [30,31]. While alcohol dehydrogenase accounts for “essentially 
all” alcohol metabolism (low Km: 0.2-2 mM), CYP2E1 is involved when alcohol concentrations are 
high (high Km: 8-10 mM) [32]. However, CYP2E1 is a major metabolic pathway for ethanol 
oxidation in the central nervous system [33]. Chronic alcohol intake generates toxic acetaldehydes, 
resulting from altered ethanol degradation pathways [30]. The consequences of chronic alcoholism 
include fatty liver disease, cirrhosis and alcoholic hepatitis [34]. 
 
  Metadoxine has been shown to play a crucial role in the regulation of GABA 
neurotransmission [35], the dysregulation of which has been closely linked to attention deficit and 
hyperactivity disorder (ADHD) [36–39]. Fragile X syndrome was first suspected in 1943 by Martin 
and Bell [40]. Characterised by mental retardation, it is caused by expansion of a CGG trinucleotide 
in the locus Xq27.3 on the X chromosome [41,42]. Such a mutation inhibits the FMR1 gene (fragile 
X mental retardation 1), which, in turn, disrupts the FMR protein, involved in the downstream signal 
of glutamate and responsible for the stabilisation of protein translation [42]. In fine, such a mutation 
alters both glutamate and GABA neurotransmissions [43–46].  
 
  Because metadoxine is a simple combination of vitamin B6 and pyroglutamic acid, our 
objective is to provide an insight of how such basic molecules could benefit a wide range of patients, 
being admitted in clinics for acute illness to life-threatening diseases. This systematic review will 





2- Material and Methods 
 
We followed the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) [69]. This review protocol has been registered in the International Prospective Register 
of Systematic Reviews (PROSPERO) with the registration number CRD42017072964 and can be 
accessed at the following URL address: 
http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017072964 
 
Eligibility and exclusion criteria 
 Eligible studies were all published trials investigating metadoxine in humans, regardless of 
regimen, length and outcomes. Exclusion criteria were studies not abstracted, studies performed on 
rodents, in vitro studies, retrospective studies and review articles. Studies not written in English 
were only included if abstract was translated into English. 
 
Information sources and search methods 
 Computerised literature searches were performed in three different databases: MEDLINE©, 
the European Union Clinical Trials Register and the ClinicalTrials.gov registry. We used the single 
word “metadoxine” as the search equation in late July 2017 for our systematic review. To access 







   Essential information extracted from all studies included: 1- trial type (if applicable), 2- 
location, 3- physiopathologies of enrolled patients, 4- number of patients enrolled in both 
metadoxine and control groups (if applicable), 5- number of adverse events (if applicable), 6- main 
outcome(s), and 7- possible bias. 
 
Risk of bias in individual studies 
  All included studies were evaluated by the reviewers. As suggested by the Cochrane 
Collaboration handbook [47] and the GRADE framework, risks of bias for each study were 
examined as follows: 1- random sequence generation (selection bias), 2- allocation concealment, 3- 
blinding, 4- Accounting of patients and outcome events, 5- selective reporting, and 6- overall risk 
of bias. Please refer to Table 2 for risk of bias across the included studies. 
 
Summary measures 
  Outcomes consisted of efficacy, adverse effects, survival rates and improvement of 
symptoms, regardless of pathologies.  Efficacy was defined as improved symptoms compared to 
placebos or reference drugs. Adverse effects (or adverse events) were defined as the appearance of 
one (or more) untoward symptom(s). Survival rates were measured as the proportion of patients still 








Selection of studies 
  Figure 4 shows the flow diagram of study design. With the search equation, 66 studies were 
identified through the MEDLINE© database, all of which were assessed for eligibility. Out of those 
initial 66 studies, 50 were excluded according to the exclusion criteria. Indeed, 18 studies were 
performed on rodents [48–65], 4 were in vitro studies [66–69], 10 studies had no abstracts  [70–79], 
13 were review articles [1,22,80–90], 2 studies were performed retrospectively [91,92] and 3 studies 
were excluded after assessment for eligibility, due to the unavailability of these articles, the written 
languages or insufficient details within abstracts [93–95]. Out of the initial 13 studies from the 
ClinicalTrials.gov database, 10 were excluded, among which two are still recruiting and eight have 
no available results. Therefore, 19 studies were eligible for review. However, 3 studies were present 
in duplicates and were therefore removed from eligibility. Finally, a total of 16 studies were included 
in the present review (Figure 4). 
 
Characteristics of studies 
  Table 1 presents all the extracted information. In total, 731 patients were enrolled in the 
metadoxine group while 721 were enrolled in the control group. However, a further 36 patients were 
given metadoxine without being compared to the appropriate controls [96], giving rise to some bias 
concern. Sixty patients were enrolled in the study by Rizzo and colleagues, but we did not find 
further information about subgroup numbers, although patients receiving metadoxine were indeed 
compared to patients receiving placebos [97]. Acute doses of metadoxine varied from 300 to 900 
mg while doses chronically administered ranged from 500 to 2000 mg/day over 10 to 90 days. 
Routes of administration were different according to pathologies. Indeed, intravenous metadoxine 
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was used for acutely administered metadoxine for patients under alcohol intoxication, while per os 
administration was preferred for long-term treatment. Note that infusion of metadoxine was used in 
one study [35]. Interestingly, one study [98] used washout periods to determine how attention may 
improve after a single dose of metadoxine (700 to 1400 mg). Whether such a study can be considered 
as using a chronic metadoxine protocol is an open question. Among all the studies, pathologies 
varied from chronic alcoholism, acute alcohol intoxication, alcoholic and non-alcoholic hepatitis, 
alcohol liver disease, to attention deficit and hyperactivity disorder. Main outcomes are summarised 
in Table 1. 
 
Risk of bias within studies 
  Nine trials used a randomized and double-blind technique. Two trials were not randomised 
in design [2,96]. Four studies were designed as open-label protocols [99–102]. One study did not 
compare patients receiving metadoxine to patients receiving placebos and may therefore introduce 
some degree of bias [96]. 
 
Synthesis of results 
  Table 1 summarises all main outcome of the 16 studies included within the present 
systematic review. 
 Risk of bias is displayed in Table 2. 
Table 3 presents the exhaustive list of clinical trials (n=13) registered in the 
ClinicalTrial.gov database, as of late July 2017. Note that two trials are still recruiting patients 
suffering from non-alcoholic steatohepatitis. A minority of these clinical trials (n=3) have published 
results. Two trials have available but not yet published results. These results can be accessed through 
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the database tabular. Note that a phase III clinical trial on ADHD patients (NCT02477748) was 
terminated by the Food and Drug Administration (FDA, U.S.A.) due to possible adverse events. 
However, it was argued that previous studies found opposite results (see discussion below). Results 
on Fragile X syndrome are not yet available (NCT02126995). 
 
4- Discussion 
  Only one drug-induced side effect has been reported in humans in the form of a skin rash 
[103]. Therefore, metadoxine has been considered safe to use by some [91,99,100]. The safety of 
metadoxine seems to have been ascertained, although some adverse events were reported.  
 
  In healthy volunteers, metadoxine reduced the half-life of ethanol [1]. After acute alcohol 
intoxication, metadoxine (300 mg/kg, intravenously) improved at least one degree of intoxication 
in 17 out of 26 patients presenting clinical signs of alcohol intoxication [100]. Another clinical study 
has shown that a single intravenous metadoxine administration (900 mg) significantly decreases the 
half-life of ethanol in the blood (from 6.7 hours to 5.4 hours) [103]. As an immediate consequence, 
the authors therefore witnessed faster recovery rates in metadoxine-treated patients than in placebo-
treated patients (respectively under 1 hour and over 2 hours). In another study using a similar 
protocol, metadoxine given intravenously as a bolus at a dose of 300 mg (with a second identical 
dose only if necessary) improved somatic and psychological symptoms of patients presenting acute 
alcohol intoxication in the emergency room [22].  
 
  In chronic alcoholism, liver functions are impaired [34,104]. In a study involving 136 
alcoholic patients, 1500 mg/day (divided into 3 daily doses) of metadoxine for 90 days significantly 
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improved liver functions quicker than placebos [105]. As a matter of fact, improved liver functions 
were here characterised by decreased degrees of steatosis (abnormal retention of lipids), decreased 
serum levels of  bilirubin, gammaglutamyl transpeptidase, cholesterol and triglycerides. Such results 
were also confirmed in another clinical trial including 75 patients receiving 1000 mg/day of 
metadoxine, split into 2 daily doses [106]. Alcohol abstinence was, alone, sufficient in improving 
liver functions in two other studies [73,105]. In another study, authors concluded that metadoxine 
allows a faster recovery through restored hepatic glutathione levels as well as enhanced oxidation 
of both ethanol and acetaldehyde, based upon their pre-clinical results [105,107]. Another laboratory 
found that 10 days of metadoxine treatment (1800 mg/day via two saline infusions) directly 
improved abstinence, reducing therefore the need for benzodiazepine therapy [35]. It should be 
noted that abstinence remains the most important therapeutic measure for improved liver functions, 
as others have agreed [73]. 
 
  In an open-label study, 1500 mg/day of metadoxine was associated with other frequently-
used molecules to determine survival rates of patients suffering from severe alcoholic hepatitis 
[102]. A 30-day co-administration treatment of metadoxine (1500 mg/day, in 3 daily doses) with 
either prednisone (40 mg/day, once daily) or pentoxifylline (1200 mg/day, in 3 daily doses) 
significantly improved survival rates at 3 and 6 months, compared to patients only receiving 
prednisone or pentoxifylline. Interestingly, patients receiving the combined therapy were able to 
maintain greater abstinence than those receiving monotherapy [102], as observed in older studies 
[2,97]. Another clinical trial, using the same protocol, led to similar results, but this study also 
revealed the reduced development of encephalopathy and hepatorenal syndrome as well as improved 




  Because greater alcohol abstinence was observed in patients under metadoxine therapy, 
probable metadoxine-induced anti-craving effects were suspected [2,64,92,97]. Such effects, if 
clearly demonstrated, may be mediated in the central nervous system. Ethanol disrupts neuronal 
excitability via complex ionic modulations of synaptic currents. Indeed, ethanol can target voltage-
gated and dihydropyridine-sensitive calcium channels, gamma aminobutyric acid (GABA) 
receptors, adenosine receptors and transporters, G protein-coupled inwardly-rectifying potassium 
channels (GIRKs) as well as N-methyl-D-aspartate (NMDA) receptors [108–115]. Therefore, the 
effects of metadoxine on the central nervous system (CNS) were also investigated in different 
pathologies, such as ADHD and Fragile X syndrome. 
 
  Among the worldwide population, ADHD affects 6-7% of children if diagnosed via the 
Diagnostic and Statistical Manual of Mental Disorders, fourth edition [116]. The prevalence of 
ADHD in the US child population has been estimated at 8.7% [117], a rate that is very similar to 
the UK figure of 8% of school-aged children [118]. Current pharmacotherapy for ADHD can induce 
adverse events [119–123]. Core ADHD symptoms include inattention, hyperactivity as well as 
impulsivity [124,125]. Such symptoms were found to be significantly improved following 
metadoxine treatment (6 weeks of 1400 mg/day, comprised of 490 mg/day of immediate release and 
910 mg/day of extended release), or even after a single 1400 mg acute administration [98,126,127]. 
Following acute metadoxine intake, such effects lasted from 3 to 5 hours. Under chronic metadoxine 
treatment, the effects were found to be significant after 2 weeks and lasted until the treatment was 
terminated. However, a single dose of 700 mg of metadoxine was insufficient to improve ADHD 
scores [98]. It is known that ADHD patients present decreased GABA levels in both the 
somatosensory and motor cortices [128] as well as up-regulated GABAergic inhibitory functions in 
frontal, temporal and cingulate regions [129]. Moreover, prefrontal and cingulate glutamate 
neurotransmissions were altered in ADHD patients [130,131]. A unique advantage to treating 
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ADHD patients with metadoxine resides in its pharmacological properties. Indeed, compared to 
already approved ADHD medication, metadoxine does not involve the blockade of neurotransmitter 
uptake nor psychostimulation. Its ability to improve cognition may be interesting in other diseases 
involving cognitive impairments such as Alzheimer’s and Parkinson’s diseases as well as 
schizophrenia. We believe that the effects of metadoxine on ADHD symptoms could be attributed 
to the roles of both vitamin B6 and pyroglutamic acid in replenishing GABA and glutamate levels, 
respectively. Indeed, as seen in Figure 2, increases in the cellular content of vitamin B6 could lead 
to increases in GABA levels. Similarly, Figure 3 shows that pyroglutamic acid can be transformed 
into glutamate by 5-oxoprolinase, thus increasing cellular content of glutamate. Furthermore, 
studies performed on animals have shown that pyroglutamic acid can increase GABA levels in the 
frontal cortex [132]. 
   
  Metadoxine was investigated in a phase II study, comparing its efficacy to placebo in 
alleviating the physiopathology of Fragile X syndrome (NCT02126995). In this study, adults and 
adolescents were given 700-1400 mg/day of metadoxine in a randomised fashion for a total of 6 
weeks. Outcome measures will focus on safety and the severity of syndromes. The results are yet to 
be disclosed. Until 2016, this new molecule for ADHD treatment was still under investigation. 
Unfortunately, early in 2017 and following a phase III clinical trial, metadoxine was believed to be 
inefficient for ADHD patients. However, 4 trials investigating metadoxine in ADHD patients have 
not yet disclosed results (NCT02126995, NCT00995085, NCT02189772 and NCT02059642). 
Based upon the Conners’ Adult ADHD Rating Scale (CAARS), 10 weeks of metadoxine (1400 
mg/day) failed to bring about significantly different results from the placebo in the 293 patients 
enrolled for a trial. Besides, a retrospective analysis of adverse neurological events with metadoxine 
in rodents has resulted in a full clinical hold of the phase III trial by the FDA (ClinicalTrials.gov 
identifier NCT02477748). This measure came as a surprise and researchers have argued that 
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metadoxine has gone through many clinical trials and side effects never occurred more frequently 
or severely than with placebos [127]. Finally, another interest for the use metadoxine is found in 
ADHD patients with alcohol abuse [82], because of its efficiency in treating alcohol abuse, as 
mentioned earlier. Indeed, alcohol abuse is a frequently observed co-morbidity in adults and 
children with ADHD [133–136]. 
 
 Since all studies presented in this review included rather small sample sizes, a major 
limitation to all findings resides in the fact that these trials are likely to report large beneficial effects, 
compared to studies with greater sample sizes [137]. Thus, caution should be taken in the 
interpretation of results arising from small trials. 
 
4- Conclusion 
To conclude, metadoxine seems efficient in treating acute and chronic alcohol exposure, 
probably due to increased ethanol metabolism. Moreover, its efficacy in reducing steatosis and 
hepatorenal syndromes has been clearly demonstrated, combined with improved survival rates. 
Metadoxine is currently under investigation for its potential benefits in ADHD and fragile X 
syndrome. Side effects are not more frequently or more severely observed than those observed using 
placebos or other approved drugs. Future fundamental and clinical studies will be needed for the 
complete understanding of the effects of metadoxine on liver and brain functions, as well as 
determining precise cellular mechanisms. While the efficacy of metadoxine in treating alcohol 
dependence and alcohol-induced liver damage has been ascertained in international studies, its 




Registration of this review 
This review protocol has been registered in the International Prospective Register of Systematic 
Reviews (PROSPERO) with the registration number CRD42017072964 and can be accessed at the 
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Figures and Legends: 
 
 
Figure 1: Chemical formula of metadoxine. Metadoxine is composed of pyroglutamic acid 







Figure 2: The role of pyridoxal 5’-phosphate (active form of vitamin B6) in different 
metabolic pathways. The active form of vitamin B6, pyridoxal 5’-phosphate, is required for the 
syntheses of neurotransmitters, sphingolipids, haemoglobin and taurine, as well as for 
glycogenolysis. Continuous arrows represent direct products while dashed arrows represent the 
need for several chemical reactions (not detailed). L-DOPA: L-3,4-dihydroxyphenylalanine, 
CoA: coenzyme A, NADP: nicotinamide adenine dinucleotide phosphate. a: 5-
hydroxytryptophan decarboxylase, b: aromatic L-amino acid decarboxylase, c: dopamine-β-
hydroxylase, d: phenylethanolamine N-methyltransferase, e: glutamate decarboxylase, f: serine 
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Figure 3: The role of pyroglutamic acid in both glutamate and glutathione metabolisms. 
Pyroglutamic acid can be obtained in vitro by heating glutamate to 180oC, resulting in a loss of one 
water molecule (top). In vivo, pyroglutamic acid is found at the centre of the glutamate/glutathione 
cycle (bottom). Glutathione exerts a negative feedback on γ-glutamylcysteine synthase (not drawn). 
The small triangle represents heating. a: 5-oxoprolinase, b: γ-glutamylcysteine synthase, c: 








































































Studies assessed for eligibility, n=66
Studies excluded, n=50
Studies performed on rodents, n=18








Studies are still recruiting, n=2
Studies have no results yet, n=8






Table 1: Basic characteristics and main outcome(s) of clinical trials investigating the effects 
of metadoxine. Note that some trials did not compare patients receiving metadoxine to control 
patients. Also, some regimen were not known. The physiopathologies of patients could be divided 
into two major categories: patients with liver disorders or patients with central nervous system 
disorders. ADHD: attention deficit and hyperactivity disorder. 
 
 
Studies Locations Pathologies Type of studies Number of patients Regimen Main outcomes
Higuera-de la Tijera et al, 
2015 [102]
Mexico Alcoholic hepatitis Randomized, open-label trial 67 metadoxine, 68 controls
1500 mg/day, for 30 
days
-Improved survival rates after 3 and 6 months of treatment.
-Greater abstinence.
Shenoy et al, 2014 [106] India Non-alcoholic hepatitis
Randomized, double blind, 
multicentre trial
75 metadoxine, 59 controls
1000 mg/day, for 
112 days
-Improvement of steatosis.
-Safety and tolerability of metadoxine is similar to 
placebo.
-Negative results on liver histology.
Manor et al, 2014 [98] Israel Inattentive ADHD
Randomized, double blind, 
single-centre trial
34 metadoxine, 35 controls
0-1400 mg once a 
week, for 3 weeks
-700 mg is ineffective.
-1400 mg improves attention.
-Safety and tolerability of metadoxine is similar to 
placebo.
Higuera-de la Tijera et al, 
2014 [101]
Mexico Alcoholic hepatitis Randomized, open-label trial 35 metadoxine, 35 controls
1500 mg/day, for 30 
days
-Improved survival rates after 3 and 6 months of treatment.
-Better response to treatment using metadoxine.
-Adverse events are similar in both groups.
Manor et al, 2013 [126] Israel Inattentive ADHD
Randomized, double-blind, 
multisite trial
60 metadoxine, 60 controls
1400 mg/day, for 42 
days
-Metadoxine is only efficacious for treating inattention in 
adults with predominantly inattentive ADHD, but not in 
adults with other forms of ADHD. 
Manor et al, 2012 [127] Israel ADHD
Randomized, double-blind, 
multisite trial
60 metadoxine, 60 controls
1400 mg/day, for 42 
days
-Metadoxine is well tolerated.
-Metadoxine is efficient in treating adults with ADHD.
Sil'vestrova et al, 2011 [96] Russia Alcohol liver disease Non-randomized study 36 patients, no controls.
500 mg/day, for 28 
days
-Improvement of drug-metabolising liver function.
Mao et al, 2009 [138] China Alcohol liver disease
Randomized, double blind, 
multicentre trial
126 metadoxine, 128 controls
1500 mg/day, for 42 
days
-Improvement of liver functions only in abstinent patients.
-Adverse events are similar in both groups.
-Metadoxine improves liver to spleen ratios.
Guerrini et al, 2006 [2] Italy Alcohol dependence
Non-randomized, follow-up 
study
58 metadoxine, 102 controls
1000 mg/day, for 90 
days
-Better rate of complete abstinence with metadoxine.
-Significantly less drop-outs with metadoxine.
Shpilenya et al, 2002 [103] Russia
Acute alcohol 
intoxication
Randomized, double blind, 
multicentre trial
29 metadoxine, 29 controls 900 mg, i.v., once
-Faster elimination of ethanol.
-Faster recovery rate.
Díaz Martínez et al, 2002 [100] Mexico
Acute alcohol 
intoxication
Randomized, open-label trial 26 metadoxine, 26 controls
300-600 mg, i.v., 
once
-Improvement of intoxication.
-Acceleration of alcohol clearance.
Vedrova et al, 2001 [139] Russia Alcohol liver disease Not specified 20 metadoxine, 12 controls
1500-2000 mg/day, 
for 30 days
-Normalisation of liver functions.
-Metadoxine does not induce adverse events.
Caballería et al, 1998 [105] Spain Fatty liver disease
Randomized, double blind, 
multicentre trial
69 metadoxine, 67 controls
1500 mg/day, for 90 
days
-Faster improvement of liver functions with metadoxine.
-Amelioration of steatosis.
-Lower proportion of patients with signs of steatosis.
Rizzo et al, 1993 [97] Italy Chronic alcoholism Randomized, double blind




-Lower need for benzodiazepine/neuroleptic therapy. 
Corsini et al, 1992 [99] Italy Chronic alcoholism
Randomized, open-label, 
multicentre trial
52 metadoxine, 20 controls
1000 mg/day, for 60 
days
-Significant reduction of mean corpuscular volume.
-Improvement of enzymatic functions (liver).
-No metadoxine-induced adverse event.
Bono et al, 1991 [35] Italy Chronic alcoholism Randomized, double blind 20 metadoxine, 20 controls
1800 mg/day 
infused, for 10 days
-Better alcohol abstinence.





Table 2: Risk of bias across included studies. Low (white), medium (grey), high (black) and  












O verall risk of bias
Higuera-de la Tijera et al, 2015 
[102]
Shenoy et al, 2014 [106]
Manor et al, 2014 [98]
Higuera-de la Tijera et al, 2014 
[101]
Manor et al, 2013 [126]
Manor et al, 2012 [127]
Sil'vestrova et al, 2011 [96] ? ?
Mao et al, 2009 [138]
Guerrini et al, 2006 [2] ? ?
Shpilenya et al, 2002 [103]
Díaz Martínez et al, 2002 [100]
Vedrova et al, 2001 [139] ? ? ?
Caballería et al, 1998 [105]
Rizzo et al, 1993 [97]
Corsini et al, 1992 [99]




Table 3: List of all clinical trials investigating metadoxine, registered in the 
ClinicalTrials.gov database and up to July 2017. Past and current (as of July 2017) clinical 
trials investigating metadoxine for its potential use in different diseases. Trials are sorted 
according to pathologies, identification number (ClinicalTrials.gov identifier) and status. Note 









































Healthy volunteers NCT01933997 Completed
